Abstract

Research Article

Therapy of Walker Carcinosarcoma with Pectin and Cyclophosphane

NY Alimzhanov, ISh Chakeev, BN Lepshin, IO Kudaibergenova, BA Shaimurzayeva, LV Serikova and Sh Jorobekova*

Published: 04 October, 2023 | Volume 7 - Issue 3 | Pages: 066-070

Scientific interest in low-molecular-weight pectins is not accidental. Despite the experimental material widely presented in the literature on the pharmacological effects of pectins, the clinical application of the developments has not yet been fully implemented. On the one hand, antitumor potential is registered in polymers with a mass of hundreds of kilodaltons, on the other hand, practically nothing is known about such in pectin derivatives weighing less than 20 kDa. In addition, the issues of assessing the nature of the pharmacological interaction of nanoscale pectin and conventional cytostatics are not covered. The aim of this work is an experimental study of the antitumor potential of low-molecular, low-esterified pectin in combination with a cytostatic agent on a model of Walker’s carcinosarcoma. Pectin therapy of Walker’s transplanted tumor in several series of experiments consistently caused inhibition of its growth from 60% to 80%. The combined use of pectin and cyclophosphane caused inhibition of tumor growth up to 72.4%. The increase in life expectancy in the “pectin + cyclophosphane” group versus the “cyclophosphane” group was 200%. It can be concluded that nanoscale pectin is a promising drug for in-depth study since it meets the criteria of primary screening (increase in animal life expectancy, inhibition of tumor growth, survival without tumor growth).

Read Full Article HTML DOI: 10.29328/journal.jro.1001056 Cite this Article Read Full Article PDF

Keywords:

Nanodimensional pectin; Cyclophosphane; Walker carcinoma

References

  1. Ovoldov Yu. Modern ideas about pectin substances. Bioorganic Chemistry. 2009; 35: 293-310.
  2. Zakaria NG, Rahman RA, Zaikal DNA, Yusoh M. Malaysian Journal of Fundamental and Applied Sciences. 2021; 17: 33-37.
  3. Azimova LB, Filatoov AV, Muchamedzhanova Myu, Turaev AC. Preparation and rheological properties of pectin, isolation using microwave radiation. Journal of Chemistry of Plant Raw Materials. 2023; 77-86.
  4. Pachmonova MO, Vasina SM, Naimova BK. Preparation and properties of pectins from food industry waste. Universum. 2023; 105: 14990. DOI10.32743/Unichem2023.
  5. Butova CN. Characteristics of pectins from non-traditional raw materials. Young Scientist. 2020; 22: C.424 - 426.
  6. Guryev AM. Chemical and pharmacological investigation of polysaccharides of higher plants and prospects of their use in the therapy of evil-qualitative neoplasms: dis ... Doctor of Pharmaceutical Sciences. Pyatigorsk. 2011; 297.
  7. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia. 2007 Aug;9(8):662-70. doi: 10.1593/neo.07433. PMID: 17786185; PMCID: PMC1950436.
  8. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005 May;7(5):522-7. doi: 10.1593/neo.04646. PMID: 15967104; PMCID: PMC1501167.
  9. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62. doi: 10.1093/jnci/94.24.1854. PMID: 12488479.
  10. Sathisha UV, Jayaram S, Harish Nayaka MA, Dharmesh SM. Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources. Glycoconj J. 2007 Nov;24(8):497-507. doi: 10.1007/s10719-007-9042-3. Epub 2007 May 25. PMID: 17525829.
  11. Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J. 1994 Dec;11(6):527-32. doi: 10.1007/BF00731303. PMID: 7696855.
  12. Dygai AM. Zueva EP, Razina TG. System of selection of natural compounds for use in oncological practice. Work experience of the Institute of Pharmacology with RAMS. Pacific Medical Journal. 2010; 10-15.
  13. Methodological recommendations for the preclinical study of drugs that have the ability to inhibit the process of metastasis and increase the effectiveness of cytostatic therapy of tumors. Guidelines for experimental (preclinical) study of new pharmacological substances. 2005; 674-682. (Russian)
  14. Sahasrabudhe NM, Beukema M, Tian L, Troost B, Scholte J, Bruininx E, Bruggeman G, van den Berg M, Scheurink A, Schols HA, Faas MM, de Vos P. Dietary Fiber Pectin Directly Blocks Toll-Like Receptor 2-1 and Prevents Doxorubicin-Induced Ileitis. Front Immunol. 2018 Mar 1;9:383. doi: 10.3389/fimmu.2018.00383. PMID: 29545800; PMCID: PMC5839092.
  15. Pérez-Loyola M. Modified pectins with activity against colon cancer. J Pharm Pharmacogn Res. 2022; 10: 616-651.
  16. Wong TW, Colombo G, Sonvico F. Pectin matrix as oral drug delivery vehicle for colon cancer treatment. AAPS PharmSciTech. 2011 Mar;12(1):201-14. doi: 10.1208/s12249-010-9564-z. Epub 2010 Dec 31. PMID: 21194013; PMCID: PMC3066368.
  17. Donadio JLS, Prado SBRD, Rogero MM, Fabi JP. Effects of pectins on colorectal cancer: targeting hallmarks as a support for future clinical trials. Food Funct. 2022 Nov 14;13(22):11438-11454. doi: 10.1039/d2fo01995g. PMID: 36314297.
  18. Liko A. In vitro evaluation of pectin-based drug delivery system for colorectal cancer-targeted drug delivery / Indonesia International Institute for Life Sciences. 2021; T202109065.
  19. Emran TB, Islam F, Mitra S, Paul S, Nath N, Khan Z, Das R, Chandran D, Sharma R, Lima CMG, Awadh AAA, Almazni IA, Alhasaniah AH, Guiné RPF. Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential. Molecules. 2022 Oct 31;27(21):7405. doi: 10.3390/molecules27217405. PMID: 36364232; PMCID: PMC9657392.
  20. Hossein G, Halvaei S, Heidarian Y, Dehghani-Ghobadi Z, Hassani M, Hosseini H, Naderi N, Sheikh Hassani S. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids. Cancer Med. 2019 Aug;8(9):4315-4329. doi: 10.1002/cam4.2334. Epub 2019 Jun 13. PMID: 31197964; PMCID: PMC6675724.
  21. Manskikh VN, Manskikh BN. Morphological methods of verification and quantitative assessment of apoptosis. Bulletin of Siberian Medicine. 2004; 63-70.
  22. Gubler EV, Genkin AA. Application of nonparametric criteria of statistics in biomedical research. L. Medicine. 1973; 143.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Similar Articles

  • Therapy of Walker Carcinosarcoma with Pectin and Cyclophosphane
    NY Alimzhanov, ISh Chakeev, BN Lepshin, IO Kudaibergenova, BA Shaimurzayeva, LV Serikova and Sh Jorobekova* NY Alimzhanov, ISh Chakeev, BN Lepshin, IO Kudaibergenova, BA Shaimurzayeva, LV Serikova, Sh Jorobekova*. Therapy of Walker Carcinosarcoma with Pectin and Cyclophosphane. . 2023 doi: 10.29328/journal.jro.1001056; 7: 066-070

Recently Viewed

Read More

Most Viewed

Read More

Help ?